Please upgrade your browser.
Programmed death ligand 1 (PD-L1) expressed on the tumour cell surface, or on neighbouring host immune cells in the tumour microenvironment, engages the programmed death 1 (PD-1) receptor on activated cytotoxic T cells and thus downregulates the tumour-directed host immune response.
Natural killer cells usually protect the body from harm, but a team from the Southern Illinois University School of Medicine, USA, has been investigating the unexpected role these cells play in the pathology of kidney cancer...
Rutgers Cancer Institute of New Jersey Collaborates with Big Ten Cancer Research Consortium on Clinical Trial for Metastatic Kidney Cancer
n conjunction with the Big Ten Cancer Research Consortium (BTCRC), Rutgers Cancer Institute of New Jersey has opened a clinical trial for patients with kidney cancer that has spread to other parts of the body (metastatic).
"Renal mass biopsy for a small renal mass can be performed accurately," the authors write. "A second biopsy should be considered in nondiagnostic biopsy cases."
The tumor vaccine MGN1601 was designed and developed for treatment of metastatic renal cell carcinoma (mRCC). MGN1601 consists of a combination of fourfold gene-modified cells with the toll-like receptor 9 agonist dSLIM, a powerful connector of innate and adaptive immunity.
Developments in the field of immuno-oncology (I-O) have ushered in a new era of hope in cancer care. This new concept has forced scientists and clinicians to think beyond the organ of origin of the tumor and wonder about the dynamic interaction between the tumor and its environment.
Duke University researchers have discovered a promising target for renal cell carcinomas
"Varlilumab is an attractive candidate for combination immunotherapy across a variety of cancers due to its target's restricted expression and strong activity in a variety of tumor models, as well as positive data and a favorable safety profile from our Phase 1 study."
This online group provides a safe, confidential space where participants can discuss the unique challenges of living with this illness while receiving support, information and guidance.
Mundipharma EDO GmbH have entered into an agreement for the development and testing of a DRP™ biomarker for Mundipharma EDO’s lead compound EDO-S101
"We are excited at the prospect of our partner Mundipharma EDO moving into Phase I with a DRP™ biomarker developed by MPI A/S,"
|NeonCRM by Neon One|